GlaxoSmithKline to get 60%-66% interest in dolutegravir, Reuters reports

GlaxoSmithKline (GSK) Chief Strategy Officer David Redfern says the company will get a 60%-66% economic interest in dolutegravis, a drug for HIV/AIDS, through a revised Shionogi deal, Reuters reports. The deal is expected to be about 1p per share dilutive in 2013 and 2014 and accretive thereafter.

View Comments (0)